Last reviewed · How we verify
2-Chromenone (COUMARIN)
2-Chromenone, also known as Coumarin, is a small molecule drug in the coumarin class targeting Carbonic anhydrase 14. However, there is limited information available on this compound, suggesting it may not be a commercially available or FDA-approved medication. As a result, its commercial status, approved indications, and safety considerations are unknown. Further research is needed to determine its potential as a therapeutic agent. Unfortunately, the provided facts do not provide a comprehensive understanding of Coumarin's clinical utility.
At a glance
| Generic name | COUMARIN |
|---|---|
| Drug class | coumarin |
| Target | Induced myeloid leukemia cell differentiation protein Mcl-1, Carbonic anhydrase 1, Carbonic anhydrase 12 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial) (PHASE2)
- Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III) (PHASE3)
- Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia (NA)
- Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia (PHASE4)
- Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care (NA)
- D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism (PHASE4)
- Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection (PHASE2)
- Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2-Chromenone CI brief — competitive landscape report
- 2-Chromenone updates RSS · CI watch RSS